Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S; SPARE study team.

Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.

PLoS One. 2013 Aug 8;8(8):e73639. doi: 10.1371/journal.pone.0073639. PMID: 23951362; PMCID: PMC3738570.

https://pubmed.ncbi.nlm.nih.gov/23951362/

Shimane K, Kawaji K, Miyamoto F, Oishi S, Watanabe K, Sakagami Y, Fujii N, Shimura K, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.

HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

Antimicrob Agents Chemother. 2013 Aug;57(8):4035-8. doi: 10.1128/AAC.00237-13. Epub 2013 May 20. PMID: 23689710; PMCID: PMC3719727.

https://pubmed.ncbi.nlm.nih.gov/23689710/

Michailidis E, Ryan EM, Hachiya A, Kirby KA, Marchand B, Leslie MD, Huber AD, Ong YT, Jackson JC, Singh K, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.

Retrovirology. 2013 Jun 24;10:65. doi: 10.1186/1742-4690-10-65. PMID: 23800377; PMCID: PMC3695782.

https://pubmed.ncbi.nlm.nih.gov/23800377/

Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, Larue RC, Patel PA, Mitsuya H, Kessl JJ, Engelman A, Fuchs JR, Kvaratskhelia M.

The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.

J Biol Chem. 2013 May 31;288(22):15813-20. doi: 10.1074/jbc.M112.443390. Epub 2013 Apr 24. PMID: 23615903; PMCID: PMC3668738.

https://pubmed.ncbi.nlm.nih.gov/23615903/

Amano M, Tojo Y, Salcedo-Gómez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H.

GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.

Antimicrob Agents Chemother. 2013 May;57(5):2036-46. doi: 10.1128/AAC.02189-12. Epub 2013 Feb 12. PMID: 23403426; PMCID: PMC3632947.

https://pubmed.ncbi.nlm.nih.gov/23403426/

Izumi K, Kawaji K, Miyamoto F, Shimane K, Shimura K, Sakagami Y, Hattori T, Watanabe K, Oishi S, Fujii N, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.

Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.

Int J Biochem Cell Biol. 2013 Apr;45(4):908-15. doi: 10.1016/j.biocel.2013.01.015. Epub 2013 Jan 26. PMID: 23357451; PMCID: PMC4136414.

https://pubmed.ncbi.nlm.nih.gov/23357451/

Togami H, Shimura K, Okamoto M, Yoshikawa R, Miyazawa T, Matsuoka M.

Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents.

J Virol. 2013 Apr;87(8):4322-9. doi: 10.1128/JVI.03208-12. Epub 2013 Jan 30. PMID: 23365453; PMCID: PMC3624392.

https://pubmed.ncbi.nlm.nih.gov/23365453/

Yuki H, Ueno S, Tatetsu H, Niiro H, Iino T, Endo S, Kawano Y, Komohara Y, Takeya M, Hata H, Okada S, Watanabe T, Akashi K, Mitsuya H, Okuno Y.

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.

Blood. 2013 Feb 7;121(6):962-70. doi: 10.1182/blood-2012-05-431429. Epub 2012 Dec 4. PMID: 23212521.

https://pubmed.ncbi.nlm.nih.gov/23212521/

Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, Hata H.

PDK1 inhibition is a novel therapeutic target in multiple myeloma.

Br J Cancer. 2013 Jan 15;108(1):170-8. doi: 10.1038/bjc.2012.527. Epub 2012 Nov 29. PMID: 23321518; PMCID: PMC3553526.

https://pubmed.ncbi.nlm.nih.gov/23321518/

Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S; Epzicom-Truvada study team.

Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.

Intern Med. 2013;52(7):735-44. doi: 10.2169/internalmedicine.52.9155. Epub 2013 Apr 1. PMID: 23545667.

https://pubmed.ncbi.nlm.nih.gov/23545667/

Michailidis E, Singh K, Ryan EM, Hachiya A, Ong YT, Kirby KA, Marchand B, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.

Cell Mol Biol (Noisy-le-grand). 2012 Dec 22;58(1):187-95. PMID: 23273211; PMCID: PMC3551986.

https://pubmed.ncbi.nlm.nih.gov/23273211/

Okuno Y, Tatetsu H, Nosaka K, Mitsuya H.

Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication.

J Clin Exp Hematop. 2012;52(2):101-6. doi: 10.3960/jslrt.52.101. PMID: 23037625.

https://pubmed.ncbi.nlm.nih.gov/23037625/

Edwards CK 3rd, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H, Kawaguchi T, Sakata KM, Cheronis J, Trollinger D, Bankaitis-Davis D, Dinarello CA, Norris DA, Bevilacqua MP, Fujita M, Burmester GR.

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.

Front Immunol. 2012 Dec 4;3:366. doi: 10.3389/fimmu.2012.00366. PMID: 23264777; PMCID: PMC3525111.

https://pubmed.ncbi.nlm.nih.gov/23264777/

Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.

Effects of substitutions at the 4′ and 2 positions on the bioactivity of 4′-ethynyl-2-fluoro-2′-deoxyadenosine.

Antimicrob Agents Chemother. 2013 Dec;57(12):6254-64. doi: 10.1128/AAC.01703-13. Epub 2013 Oct 7. PMID: 24100493; PMCID: PMC3837839.

https://pubmed.ncbi.nlm.nih.gov/24100493/

Aoki M, Danish ML, Aoki-Ogata H, Amano M, Ide K, Das D, Koh Y, Mitsuya H.

Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.

J Virol. 2012 Dec;86(24):13384-96. doi: 10.1128/JVI.07234-11. Epub 2012 Sep 26. PMID: 23015723; PMCID: PMC3503118.

Mizuhara T, Oishi S, Ohno H, Shimura K, Matsuoka M, Fujii N.

Structure-activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents.

Bioorg Med Chem. 2012 Nov 1;20(21):6434-41. doi: 10.1016/j.bmc.2012.08.030. Epub 2012 Aug 30. PMID: 23022280.

https://pubmed.ncbi.nlm.nih.gov/23022280/

Tanaka G, Nakase I, Fukuda Y, Masuda R, Oishi S, Shimura K, Kawaguchi Y, Takatani-Nakase T, Langel U, Gräslund A, Okawa K, Matsuoka M, Fujii N, Hatanaka Y, Futaki S.

CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV.

Chem Biol. 2012 Nov 21;19(11):1437-46. doi: 10.1016/j.chembiol.2012.09.011. PMID: 23177198.

https://pubmed.ncbi.nlm.nih.gov/23177198/

Mizuhara T, Oishi S, Ohno H, Shimura K, Matsuoka M, Fujii N.

Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles.

Org Biomol Chem. 2012 Sep 7;10(33):6792-802. doi: 10.1039/c2ob25904d. Epub 2012 Jul 24. PMID: 22829059.

https://pubmed.ncbi.nlm.nih.gov/22829059/

Gazon H, Lemasson I, Polakowski N, Césaire R, Matsuoka M, Barbeau B, Mesnard JM, Peloponese JM Jr.

Human T-cell leukemia virus type 1 (HTLV-1) bZIP factor requires cellular transcription factor JunD to upregulate HTLV-1 antisense transcription from the 3′ long terminal repeat.

J Virol. 2012 Sep;86(17):9070-8. doi: 10.1128/JVI.00661-12. Epub 2012 Jun 13. PMID: 22696638; PMCID: PMC3416116.

https://pubmed.ncbi.nlm.nih.gov/22696638/

Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA.

Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo.

Antimicrob Agents Chemother. 2012 Sep;56(9):4707-12. doi: 10.1128/AAC.00723-12. Epub 2012 Jun 19. PMID: 22713337; PMCID: PMC3421895.

https://pubmed.ncbi.nlm.nih.gov/22713337/

Kawano Y, Fujiwara S, Wada N, Izaki M, Yuki H, Okuno Y, Iyama K, Yamasaki H, Sakai A, Mitsuya H, Hata H.

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

Int J Oncol. 2012 Sep;41(3):876-84. doi: 10.3892/ijo.2012.1545. Epub 2012 Jul 4. PMID: 22766978; PMCID: PMC3582943.

https://pubmed.ncbi.nlm.nih.gov/22766978/

Li X, Qian H, Miyamoto F, Naito T, Kawaji K, Kajiwara K, Hattori T, Matsuoka M, Watanabe K, Oishi S, Fujii N, Kodama EN.

A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats.

Biochem Biophys Res Commun. 2012 Jul 27;424(2):257-61. doi: 10.1016/j.bbrc.2012.06.097. Epub 2012 Jun 23. PMID: 22735265.

https://pubmed.ncbi.nlm.nih.gov/22735265/

Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS.

Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

Mol Pharmacol. 2012 Jul;82(1):125-33. doi: 10.1124/mol.112.078758. Epub 2012 Apr 18. PMID: 22513406; PMCID: PMC3382833.

https://pubmed.ncbi.nlm.nih.gov/22513406/

Maeda K, Das D, Nakata H, Mitsuya H.

CCR5 inhibitors: emergence, success, and challenges.

Expert Opin Emerg Drugs. 2012 Jun;17(2):135-45. doi: 10.1517/14728214.2012.673584. Epub 2012 Apr 25. PMID: 22533737.

https://pubmed.ncbi.nlm.nih.gov/22533737/